Ever Supreme Bio Technology Co (6712) Fair Value & Analysis
Healthcare · TW · Market cap 14.1B TWD
Fair value as of: Jul 23, 2026
From 24 valuation models · updated 18 days ago
Fair value updated Jul 23, 2026, revised from 62.28 TWD to 66.27 TWD (+6.4%) since Jul 12, 2026. Share price −10.8% over the past month.
A strong business, but screening 58% overvalued on our models.
What matters now
- A high-quality business (quality 85/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The model range is unusually wide (50.56 TWD to 263.25 TWD). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 23, 2026.
How to read this chart
60‑month range 101.49 TWD – 509.42 TWD · fair‑value band 50.56 TWD – 263.25 TWD · the 156.50 TWD price screens above the 66.27 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 23, 2026.
Analysis
Ever Supreme Bio Technology Co (6712) currently trades at 156.50 TWD, while our model-based Fair Value estimate is 66.27 TWD, implying the stock looks roughly 57.7% overvalued today. The Quality Score stands at 85/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Ever Supreme Bio Technology Co generated revenue of 1.0B TWD at a net margin of 45.9%. Revenue grew 7.1% year over year. It earns a return on equity of 23.7%. The balance sheet holds a net cash position of 331M TWD. Fundamentals as of Jul 23, 2026
Our scenario range runs from 50.56 TWD (bear case) to 263.25 TWD (bull case); at 156.50 TWD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 69% below its 52-week high and 29% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -58%, 6712 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings (202.50 TWD) versus Asset-Based (10.69 TWD). Highest evidence: Residual Income (76).
Notify me when 6712 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 23, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 82 · Market factors (momentum, volatility) 48
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells in Taiwan. The company operates through two segments: Cell Preparation Business and Other Operating Business segments.
Full company description
Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells in Taiwan. The company operates through two segments: Cell Preparation Business and Other Operating Business segments. The company's products include umbilical cord mesenchymal stem cells, a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke. It also develops dendritic cell vaccine, a drug candidate in Phase II clinical trials for the treatment of malignant brain tumor; chimeric antigen receptor immune cells, a chimeric antigen receptor immune cells product; and allogeneic bone-marrow stem cells, used to treat chronic stroke, degenerative osteoarthritis, and spinal cord injuries. In addition, the company develops allogeneic umbilical cord mesenchymal stem cells (UMSC01), used to treat cardiovascular diseases and strokes. Further, it engages in the sale of other health products and related businesses; and cell preparations and investment activities in biotechnology and medical industry businesses. Ever Supreme Bio Technology Co., Ltd was incorporated in 2016 and is based in Taichung, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Ever Supreme Bio Technology Co reported revenue of 1.0B TWD in FY2025 versus 439M TWD in FY2021, a compound +23.4%/yr. Reported net income was 429M TWD in FY2025, compounding +3.8%/yr from FY2021.
6712 screens 58% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 601 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare Ever Supreme Bio Technology Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Ever Supreme Bio Technology Co (6712) overvalued or undervalued?
What is the fair value of 6712?
What is the quality score of 6712?
What is the revenue of Ever Supreme Bio Technology Co (6712)?
What is the net profit margin of 6712?
Does Ever Supreme Bio Technology Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Ever Supreme Bio Technology Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.